SYDNEY, April 28, 2026, 08:04 AEST
AustralianSuper trimmed its stake in Cochlear Limited to 5.02%, down from 7.24%, according to a filing submitted late Monday. That leaves the retirement fund hovering just above Australia’s key substantial-holder disclosure threshold, after Cochlear endured a sharp selloff. The filing shows AustralianSuper now holds 3.28 million ordinary shares, a drop from 4.73 million previously.
The timing of the filing is key, coming just after Cochlear’s profit warning and while investors are still gauging if the sharp drop in shares last week has reached bottom. On Monday, Cochlear stock changed hands at A$95.25, down 2.16% for the day. That follows Wednesday’s historic 40.7% plunge, which saw the shares finish at A$99.58.
“Substantial holding” just means a disclosure threshold, not an offer to take over. In Australia, anyone with relevant interests in 5% or more of a listed company’s voting shares typically needs to disclose that stake—and any material changes after that also have to be reported.
Cochlear slashed its FY26 underlying net profit outlook last week, now expecting A$290 million to A$330 million, down sharply from its earlier range of A$435 million to A$460 million. This underlying figure excludes certain items Cochlear considers non-core. The downgrade was blamed on sluggish implant demand in developed markets, ongoing Middle East instability, a firmer Australian dollar, and extra costs as the company retools its cost structure.
The downgrade caught investors off guard. Reuters noted the new guidance midpoint lands far below Visible Alpha’s A$402.5 million consensus. Shares wrapped up Wednesday at their lowest level since March 2016.
Chief Executive Dig Howitt pointed out that adult and senior hearing loss continues to be viewed as a discretionary intervention—highlighting Cochlear’s ongoing effort to “medicalise hearing loss.” He added that the company is standing by its “market leadership,” crediting that position to uptake of the Nucleus Nexa system.
Cochlear pointed to a 13% jump in services revenue for the third quarter, measured at constant currency, with acoustics revenue up 11%. Constant currency strips out the impact of exchange-rate moves—a relevant metric for companies like Cochlear with significant overseas earnings.
Reactions from analysts and investors skewed negative. Anna Milne, a portfolio manager at Wilson Asset Management, said the scale of the downgrade and doubts about the turnaround “shocked the market.” Steve Wheen at Jarden said it was “far worse than anticipated.” Richard Coppleson of Bell Potter didn’t hold back, labeling the earnings cut “extraordinary.” Wilson Asset Management
Competition is heating up as well. Jarden’s Wheen pointed out rising pressure from Med-El and Advanced Bionics, noting Cochlear’s price advantage doesn’t seem to be sticking in the U.S., the report says. That’s a key issue, given Cochlear’s investment appeal has traditionally relied on its premium lineup, scale, and dominant share in implantable hearing devices.
The trouble for Cochlear might not stop with April’s downgrade. The company flagged potential receivables provisions linked to the Middle East conflict—possibly as much as A$10 million. Lower output could shave roughly A$20 million off the gross margin. Reshaping the cost base won’t come cheap either; management expects to spend somewhere between A$18 million and A$25 million. On top of that, a foreign-exchange hit after tax could mean another A$25 million drag in the second half.
Monday’s AustralianSuper notice adds to evidence that big shareholders are still shifting positions after the profit warning. The company hasn’t called demand structurally broken. Investors now want to know how long it will take to find out.
